Day: August 5, 2024

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results – Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful Results

Vascular Therapies Completes Enrollment in the ACCESS 2 Study, a Phase III Multinational Randomized Clinical Trial of the Sirolimus Eluting Collagen Implant (Sirogen) for the Surgical Creation of Arteriovenous Fistula for Hemodialysis Vascular Access

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company...

error: Content is protected !!